Biomm (BIOM3) Stock Overview

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. The company was founded in 2001 and is headquartered in Nova Lima, Brazil.